Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study

PURPOSE: During the alirocumab open-label extension study ODYSSEY OLE (open-label extension; NCT01954394), physicians could adjust alirocumab dosing for enrolled patients, who were diagnosed with heterozygous familial hypercholesterolemia (HeFH) and who had completed previous phase III clinical tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Langslet, Gisle, Hovingh, G. Kees, Guyton, John R., Baccara-Dinet, Marie T., Letierce, Alexia, Manvelian, Garen, Farnier, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334259/
https://www.ncbi.nlm.nih.gov/pubmed/32363493
http://dx.doi.org/10.1007/s10557-020-06984-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334259/
https://www.ncbi.nlm.nih.gov/pubmed/32363493
http://dx.doi.org/10.1007/s10557-020-06984-0

Ejemplares similares